The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Research Funding - ViewRay
A single-institution experience of acute toxicities in patients treated with short course hypofractionated radiotherapy in locally advanced rectal cancer.
 
Katie Nadine Lee
No Relationships to Disclose
 
Shane Neibart
Stock and Other Ownership Interests - NexImmune
Consulting or Advisory Role - BioSapien; Hibiscus Capital Management
 
Alexander D. Droznin
No Relationships to Disclose
 
Mai Anh Huynh
No Relationships to Disclose
 
Christian V. Guthier
No Relationships to Disclose
 
Brandon E. Turner
No Relationships to Disclose
 
Neil E. Martin
No Relationships to Disclose
 
Miranda B. Lam
Consulting or Advisory Role - Abbvie
 
Luke Peng
No Relationships to Disclose
 
Peter C. Enzinger
Consulting or Advisory Role - ALX Oncology; Amgen; Arcus Biosciences; Arcus Biosciences; Astellas Pharma; AstraZeneca; Bayer; Blueprint Medicines; Boehringer Ingelheim; Bristol-Myers Squibb/Celgene; Celgene; Chimeric Therapeutics; Chimeric Therapeutics; Coherus Biosciences; Daiichi Sankyo; Eisai; IDEAYA Biosciences; Legend Biotech; Legend Biotech; Lilly; Loxo; loxo; Merck; Novartis; Ono Pharmaceutical; Sanofi; SERVIER; Taiho Oncology; Taiho Pharmaceutical; Takeda; Takeda; Turning Point Therapeutics; Turning Point Therapeutics; Xencor; Xencor; Zymeworks
 
Jeffrey A. Meyerhardt
Honoraria - Merck
Research Funding - Boston Biomedical (Inst)
 
Harvey J. Mamon
Honoraria - UpToDate
Consulting or Advisory Role - Merck Sharp & Dohme